Vincenzo Libri

Gower Street
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses.

ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses.

Journal: Vaccine

Published: March 19, 2026

Mild-to-moderate depressive symptoms impact on self-reported outcome measures in clinical trials for neurodegenerative diseases.

Mild-to-moderate depressive symptoms impact on self-reported outcome measures in clinical trials for neurodegenerative diseases.

Journal: Clinical trials (London, England)

Published: December 01, 2025

Third exposure to COVID-19 infection or vaccination differentially impacts T cell responses.

Third exposure to COVID-19 infection or vaccination differentially impacts T cell responses.

Journal: The Journal of infection

Published: July 18, 2025

Investigation of Influenza A(H5N1) Virus Neutralization by Quadrivalent Seasonal Vaccines, United Kingdom, 2021-2024.

Investigation of Influenza A(H5N1) Virus Neutralization by Quadrivalent Seasonal Vaccines, United Kingdom, 2021-2024.

Journal: Emerging infectious diseases

Published: May 29, 2025

Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy.

Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy.

Journal: Annals of neurology

Published: March 25, 2025

Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial.

Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial.

Journal: The Journal of infection

Published: March 11, 2025

Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.

Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.

Journal: Lancet (London, England)

Published: October 07, 2024

Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling study.

Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling study.

Journal: The Lancet. Infectious diseases

Published: April 11, 2024

Exploring Analysis Approaches for Using the Dopamine Transporter Striatal Binding Ratio in Early- to Mid-Stage Parkinson's Disease Modification Trials.

Exploring Analysis Approaches for Using the Dopamine Transporter Striatal Binding Ratio in Early- to Mid-Stage Parkinson's Disease Modification Trials.

Journal: Movement disorders clinical practice

Published: April 10, 2024

Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study.

Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study.

Journal: The Lancet. Neurology

Published: November 21, 2023

SARS-CoV-2 mucosal neutralising immunity after vaccination.

SARS-CoV-2 mucosal neutralising immunity after vaccination.

Journal: The Lancet. Infectious diseases

Published: August 25, 2023

Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].

Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].

Journal: The Journal of infection

Published: April 13, 2023

Showing 1-12 of 46

Last Updated: 09/26/2026